Kornimate/medical-research-clean huggingface dataset:
effectiveness of artificial intelligent based mhealth system to reduce acs patients bleeding events after pci

Conditions: Acute Coronary Syndrome; Percutaneous Coronary Intervention; Bleeding

Summary: the present study was designed to observe the effectiveness of artificial intelligent based mhealth system(chronic disease management system) to reduce bleeding events in acs patients undergoing pci.


Eligibility criteria:
inclusion criteria: age≥18 years, male or female; confirmed acute coronary syndrome patients; undergo percutaneous coronary intervention (pci) treatment; good command of smart phones agree to participate in this clinical study and sign a written consent form. exclusion criteria: acs admission deemed secondary to other cause such as traffic accidents, trauma, severe upper gastrointestinal bleeding, surgery, or procedure; patients who are not intend to attend 1 year of follow-up study or investigators find that patients are not able to comply with the study's requirements; pregnant women or lactating women; investigators consider patients who were not suitable for participation with other reasons

Keywords: acute coronary syndrome percutaneous coronary intervention bleeding
intracellular pharmacokinetics of zidovudine triphosphate in maternal and infant cord blood mononuclear cells.

Conditions: HIV Infections; Pregnancy

Summary: to determine the levels of zidovudine triphosphate ( azt-tp ) in maternal and fetal cord blood mononuclear cells. to determine the ratio of azt-tp to endogenous nucleoside triphosphate levels in maternal and fetal cells. to determine the extent of drug transfer through the feto/placental unit.


Eligibility criteria:
vitamin d and stroke

Conditions: Stroke

Summary: stroke remains one of the most devastating neurological diseases, often causing death, or gross physical impairment. it is the second most common cause of death worldwide and a major cause of acquired disability in adults.vitamin d deficiency has been reported to contribute to the risk of cardiovascular disease especially stroke.

this case -control observational prospective study will conducted on fifty patients with first -ever acute onset stroke within seven days (25 patients with hemorrhagic stroke and 25 patients with ischemic stroke )

Eligibility criteria:
inclusion criteria: * onset is within one week * confirmed stroke by brain cat and / or mri scan either haemorrhage or infarction exclusion criteria: * cognitive and mental changes * recurrent stroke * hepatic and renal impairment * endocrinal diseases * steroid therapy * vitamin d or ca supplementation * previous fractures * bone diseases * brain neoplasm, * autoimmune diseases * history of acute and chronic inflammatory diseases * malignancy, * trauma * surgery * acute vascular diseases that occurred within four weeks prior the onset of stroke * history myocardial infarction ˂3 months.

Keywords: vitamin d stroke parathormone
role of the pronator quadratus in distal radius fractures

Conditions: Radius; Fracture, Lower or Distal End

Summary: the skin, the bones, and most muscles received branches from the source arteries of at least two angiosomes, thus revealing one of the important anastomotic pathways by which the circulation is reconstituted in those cases where a source artery is interrupted by disease or trauma. there are numerous metaphyseal-epiphyseal branches arise within the pronator quadratus and the anterior interosseous artery and course towards the distal radius. these branches may be fundamental to the healing of the distal radius fractures and make nonunion a rare complication. the aim of this study is the evaluation of the role of the pronator quadratus muscle and its repair in volar approach in distal radius fractures treated with plate fixation.

nonunion is an extremely rare complication in distal radius fractures and is most likely to occur in patients with conditions such as diabetes, peripheral vascular disease, or alcoholism. diagnosis of nonunion is based on the absence of radiographic signs of union at 6 months. treatment should be individualized but options are reconstructive procedures or wrist arthrodesis. in volar plating and often by the fracture injury itself, the complete pronator quadratus is stripped off the volar radius. thus, the intraosseous collateral circulation must be sufficient for clinical healing. any operative approach to the distal radius fracture should not compromise both volar radial and the dorsoulnar arteries. while the branches to the pronator quadratus must be sacrificed in a palmar approach, the distal perforator can and should be spared. this is true even in the flexor carpi radialis extended approach. in distal radius fractures, when the normal outward flow of blood through the cortex is blocked, the periosteal arterioles have more ability than medullary arterioles to function and proliferate.

Eligibility criteria:
inclusion criteria: * distal radius fractures with intra-articular fragment, comminuted or displaced fracture * adults between 18- 90 years old exclusion criteria: * children * non displaced distal radius fractures treated with immobilization. * adults older than 90 years old

Keywords: distal radius fractures pronator quadratus osteosynthesis
non-incised papillae surgical approach (nipsa) with and without graft

Conditions: Periodontitis; Periodontal Diseases; Periodontal Pocket; Periodontal Attachment Loss

Summary: this study compared the clinical outcomes of the non-incised papila surgical approach (nipsa) alone and with grafting biomaterial.


Eligibility criteria:
inclusion criteria: * patients diagnosed with periodontitis. * plaque index and bleeding index of \< 30%. * periodontal lesions with pocket probing depth \> 5 mm. * intrabony defect \> 3 mm. * intrabony defect configuration including a 1 and/or 2-wall component, always involving the buccal wall. exclusion criteria: * patients with systemic diseases that contraindicated treatment. * third molars. * teeth with incorrect endodontic or restorative treatment.
evaluation of streptococcus pneumoniae serotypes prevalence using a urinary kit

Conditions: Community-acquired Pneumonia

Summary: this is an epidemiology study for the prevalence and serotypes of pneumococcus pneumoniae in hospitalized patients with community acquired pneumonia (cap). the serotypes of the pneumococcus pneumoniae will be determined by a urinary antigen assay. this is a single center, non-interventional observatory study.

patients admitted to the medical wards with a provisional diagnosis under "pneumonia","chest infection" or "fever" will be screened by research assistants. patients eligible with the inclusion criteria will be recruited into the study. informed consent will be signed for those patients willing to participate in the study. patient will be asked to save approximately 40 ml of urine. the urine sample will be processed in local laboratory and shipped out to a commercial lab for detection of any pneumococcal pneumoniae, and if present, serotyping will be performed at the same time using the same urine sample by urinary antigen assay. meanwhile patients will be managed as usual by their clinical teams. investigations and treatment will be offered by the clinical team as deemed necessary. the study team will only perform collection of urine and will not interfere the clinical management of the patients. positive results would be informed to the clinical teams for the appropriate action.

Eligibility criteria:
inclusion criteria: * admitted with signs and symptoms suggestive of pneumonia exclusion criteria: * 1. nosocomial pneumonia which is acquired \>= 48 hours after hospital admission. 2. pneumonia which are already known to be caused by pathogens other than pneumococcus pneumoniae.
pmmhri - familial hypercholesterolemia registry

Conditions: Familial Hypercholesterolemia

Summary: the registry is maintained at the regional centre for rare diseases, established in 2016, within polish mother's memorial hospital research institute. this facility diagnoses and treats over 80 distinct rare diseases in patients from across the country, including those with phenotypically or genetically confirmed familial hypercholesterolemia (fh).

all consecutive patients diagnosed with fh, including both children and adults, are being enrolled from december 2018 to may 2024. each patient receives a consultation with a clinical geneticist and a dietitian, who provide recommendations for cascade screening among family members and promote a healthy and balanced diet. the study includes all index cases, with children also serving as index cases. the pmmhri fh registry is managed by physicians from the rcrd, who exclusively make all diagnostic and treatment decisions. the purpose of the registry is to investigate the clinical characteristics, diagnosis, management, achievement of therapeutic goals, and outcomes of fh patients. inclusion criteria are based on phenotypic or genetic diagnosis of fh. phenotypic diagnosis is conducted using the dutch lipid clinic network criteria for adults, and the simon broome criteria for children. during the baseline visit, comprehensive data collection includes all available lipidogram results, aiming to obtain naive ldl-c values, highest values, and treated values. all data collected during the enrollment period are included in the study.

Eligibility criteria:
inclusion criteria: * fh diagnosis exclusion criteria: -

Keywords: familial hypercholesterolemia
abc trial: awakening and breathing controlled

Conditions: Aging; Respiration, Artificial

Summary: the purpose of this study is to determine the impact of a new rn/rrt (registered nurse/registered respiratory therapist) directed 2-step protocol to wean patients off of a ventilator. this protocol involves daily attempts to halt sedation (spontaneous awakening trials) combined with daily assessments of patients while they are breathing on their own (spontaneous breathing trials).

unnecessary delays in removing patients from mechanical ventilation increase morbidity, mortality, and cost. according to recently published guidelines, the current standard of care for weaning involves the daily assessment of patients while they are breathing spontaneously, also known as spontaneous breathing trials (sbt). while there are important data to support a daily cessation of sedatives and analgesics to the point of patient awakening, the benefit of combining such a daily spontaneous awakening trial (sat) and an sbt is not known. this multi-center, randomized controlled trial will test whether a 2-step process of weaning that combines a daily awakening trial (achieved by stopping all sedatives and narcotics every morning) with a daily spontaneous breathing trial is superior to the current standard of care. the number of days the patient is able to live off the ventilator is the primary question being studied. the secondary questions include the number of days the patient is in intensive care unit (icu) and the hospital, the complications associated with being on the ventilator (such as the duration and severity of delirium and coma), and in-hospital and one-year mortality. also, cognitive, psychological, and functional/quality of life outcomes will be measured at discharge and 3 and 12 months later. in addition, the study will measure plasma drug levels twice daily on five sequential days within 30 minutes of testing with highly reliable and well validated instruments to measure sedation level (i.e., rass) and delirium (i.e. cam-icu).

Eligibility criteria:
inclusion criteria: * recently on mechanical ventilation (less than 2 weeks prior to enrollment) * require mechanical ventilation for more than 12 hours * over 18 years old * under the services of medicine, cardiology, and neurology exclusion criteria: * admission after cardiopulmonary arrest * inability to obtain informed consent * existence of an extubation order at the time of the evaluation * dependence upon mechanical ventilation for 2 weeks prior to enrollment

Keywords: mechanical ventilation delirium sedation scoring cognitive impairment ventilation weaning
a multicenter trial enrolling men with advanced prostate cancer who are to receive combination radiation and sipuleucel-t

Conditions: Castrate Refractory Metastatic Prostate Cancer (mCRPC)

Summary: radiation in combination with provenge based immunotherapy may improve outcomes seen on imaging as well as immunologic monitoring. this study will assess the effect of radiation therapy to augment anti-tumor responses from immune therapy with provenge.

it is common knowledge that the host can make anti-tumor immune responses, although often these are ineffective in causing tumor regression. boosting these responses with immunotherapy is therefore an attractive, relatively benign adjunctive cancer treatment. little is known in regards to how standard anti-cancer therapies like radiation therapy might interact with immunotherapy in a clinical setting. we are interested in knowing if the tumor cell death occasioned by radiation therapy might augment anti-tumor responses from the immune therapy, provenge. the tentative assumption is that cell death following radiation therapy will stimulate anti-tumor immunity, which could provide a more permanent solution to curing cancer and discouraging tumors from spreading throughout the body. in order to find out if this assumption is correct, for patients undergoing radiation 28 days prior to provenge, highly developed, laboratory analyses for tumor-specific immunity and imaging will be performed.

Eligibility criteria:
inclusion criteria: subjects will be recruited from the population of patients who are castrate refractory metastatic prostate cancer (mcrpc) and have made the decision to be treated with radiation therapy to one or more metastatic sites of concern followed at least 28 days later by provenge. exclusion criteria: the potential subject is unwilling or hesitant to participate for any reason and/or fails to complete the appropriate informed consent form.
powered echelon device in vats surgery

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: this study aims to collect real world outcomes of video-assisted thoracoscopic surgery (vats) for lung cancer (lobectomy, wedge resection) using echelon flex™ powered endopath® staplers 45 mm and/or 60 mm (study devices).

the european prospective observational multi-center cohort study aims to collect real-world outcomes of consecutive patients scheduled for vats lobectomy for histologically confirmed non-small cell lung cancer (nsclc) or scheduled for vats wedge resection for undiagnosed pulmonary nodule or metastasis from colorectal cancer (crc) in accordance with their institution's standard-of-care (soc).

Eligibility criteria:
inclusion criteria: * histologically confirmed nsclc (up to and including stage ii) for patients undergoing vats lobectomy. for patients undergoing wedge resection for undiagnosed pulmonary nodule or metastasis from crc, a malignant diagnosis may be confirmed post-operatively. * scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung * willing to give consent and comply with evaluation and treatment schedule * at least 18 years of age exclusion criteria: * active bacterial infection or fungal infection * systemic administration (intravenous or oral) of steroids (within 30 days prior to study procedure) * chemotherapy or radiation therapy for lung cancer may not be performed for 30 days prior to the procedure * scheduled concurrent surgical procedure other than wedge resection or lobectomy (central venous access - e.g. port placement, mediastinoscopy with lymph node sampling, and vats lymphadenectomy are allowed); * prior history of vats or open lung surgery

Keywords: nsclc
organoid-driven chemotherapy choice in metastatic pancreatic cancer patients.

Conditions: Pancreas Neoplasms; Pancreatic Neoplasms; Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma Metastatic

Summary: pancreatic cancer is burdened by an extremely low survival rate. survival chances reduce even further when the tumor spreads to other organs such as lymphnodes, liver or lungs. when the tumor cannot be surgically resected, the only valid curative option is represented by chemotherapy. however, therapies available to date have limited efficacy and they do not specifically target the biological characteristics of the tumor. the aim of the project is to validate a new technology called \&#34;patient-derived organoids\&#34; (pdos) in predicting the best drugs for the treatment of pancreatic cancer based on the tumoral characteristics and behavior. in order to generate pdos a sample of tumoral tissue will be collected during a small surgical procedure, called laparoscopy. pdos represent mini, three-dimensional copies of the original tumor, of which they maintain its behavior and aggressiveness. through the dna and rna analysis of the tumor, the aim is to predict the best available drug by screening thousands of potentially effective compounds. once identified, drugs will be tested in vitro on pdos and the most efficient drug in controlling the tumor will be administered to the patient, once the present standard-of-care treatments fail. multiple benefits are expected from this trial. first of all, the most effective drug against their tumor based on an objective in vitro response will be provided. this might reflect in a better control of the disease and in a longer survival. targeting the chemotherapy will also imply less side-effects due to unnecessary elevated chemotherapeutic dosages, which in turn will lead to a better compliance with the therapy. eventually, all these aspects will reflect into a better quality of life.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * patients older than 18 years * patients with metastatic pancreatic ductal adenocarcinoma * at least one lesion amenable for surgical excisional biopsy * ecog performance status 0-2 * radiologically measurable disease * life expectancy \&gt; 3 months * absolute leucocyte count \&gt;1.5 g/l, platelets \&gt;100 g/l * serum creatinine \&lt;1.5 times of the upper limit of normal or clearance \&gt;50ml/min (according to the ckd-epi formula) exclusion criteria: * known allergies or intolerance to one or more compounds present in one of the 3 first line regimens approved for the trial * concomitant need for full anticoagulation that cannot be interrupted or bridged prior to tissue biopsy * ecog ps \&gt;2 * heart failure (nyha class iii-iv) * severe or uncontrolled concurrent illness * active viral infection from hiv, hbv or hcv, even if under antiretroviral treatment * myocardial infarction within the previous 6 months * patients who are pregnant or breastfeeding

Keywords: pancreatic cancer pancreatic adenocarcinoma metastatic pancreatic adenocarcinoma organoid organoid-driven chemotherapy
the clinical applicability of the 'tib' olfactory test device

Conditions: Anosmia; Hyposmia

Summary: the aim of this study was to evaluate the validity and test-retest reliability of the 'tib' olfactory test device, a new olfactory test tool developed by top international biotech, taipei, and to determine its normative values. the olfactory function of 180 subjects was evaluated using both the traditional chinese version of the university of pennsylvania of smell identification test (upsit-tc) and tib. the subjects consisted of 60 healthy volunteers (normosmic group), 60 hyposmic patients, and 60 anosmic patients. the healthy volunteers were retested with the upsit-tc and tib at an inter-test interval of at least 7 days. the cut-off scores of tib among the different groups were determined by receiver operating characteristic curve.


Eligibility criteria:
inclusion criteria: * normosmic group were self-reported absence of deficits in olfaction. hyposmic patients were loss of olfactory function with a phenyl ethyl alcohol (pea) odor detection threshold below -1. anosmic patients were loss of olfactory function with a pea threshold equal to -1. exclusion criteria: * history of sinonasal symptoms within a week before the test
a study to evaluate the safety and efficacy of medi8897 for the prevention of medically attended rsv lrti in healthy preterm infants.

Conditions: Respiratory Syncytial Virus Infections

Summary: the purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (pk), and antidrug antibody (ada) response for medi8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (ga) and entering their first respiratory syncytial virus (rsv) season.

this pivotal phase 2b study will determine if medi8897 will be efficacious in reducing medically attended rsv-confirmed lower respiratory tract infections (lrti) in healthy preterm infants entering their first rsv season. the population to be enrolled is healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days ga who would not receive rsv prophylaxis. a total of 1500 infants will be randomized 2:1 to receive either medi8897 or placebo. participants will be followed for 360 days after dosing. enrollment is planned at approximately 197 sites across the usa, canada, europe, and the southern hemisphere.

Eligibility criteria:
key inclusion criteria: 1. healthy infants born between 29 weeks 0 days and 34 weeks 6 days ga. 2. infants who are entering their first full rsv season at the time of screening. key exclusion criteria: 1. meets american academy of pediatrics (aap) or other local criteria to receive commercial palivizumab. 2. any fever (\>= 100.4°f \[\>= 38.0°c\], regardless of route) or lower respiratory illness within 7 days prior to randomization. 3. acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization. 4. active rsv infection (a child with signs/symptoms of respiratory infection must have negative rsv testing) or known prior history of rsv infection. 5. receipt of palivizumab or other rsv monoclonal antibody or any rsv vaccine, including maternal rsv vaccination.

Keywords: respiratory syncytial virus, rsv preterm infants lower respiratory tract infection
benefits of liquid oxygen in copd patients presenting desaturation during exercise.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is analyzed the impact of oxygen adjusted during exercise in copd patients without conventional for ltot but with exercise desaturation.

oxygen will be administered through nasal cannulae. patients will be provided with a tank of liquid oxygen and a rechargeable portable device. the 6 minuts walking test will be used to adjusted oxygen flow in the gfa group (to achieve a mean spo2 ≥ 90%). in the control group (gc), a 3l/min oxygen flow will be administer. oxygen is used when the patient perform physical activity. the treatment period for each patient is 6 months (3 months in the gc grup, 3 months in the gfa one).

Eligibility criteria:
inclusion criteria: * clinical stable moderate to severe copd (fev1 \ 80%) without conventional criteria for ltot, optimal medical therapy, mean spo2 ≤ 88% during the 6 minuts walking test and active life outside the home, other than active smoking or are in program respiratory rehabilitation. exclusion criteria: * current smokers - presence of respiratory failure and criteria for ltot (po2 \<55 mmhg or 55-60 mmhg associated with pulmonary arterial hypertension, chronic cor pulmonale, congestive heart failure, arrhythmias or polycythemia). - presence of impaired mobility - cognitive impairment or intellectual disability to fill in questionnaires - no acceptance of liquid oxygen - presence of active comorbidities (cardiovascular disease, rheumatologic, renal, hepatic) - participation in pulmonary rehabilitation programs

Keywords: oxygen therapy copd exercise